Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Value Type description Rank Gene Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 875 to 924 of 3228 in total 
Value Type: Measured
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dr1-associated protein 1; negative cofactor 2 alpha; dr1-associated corepressor. [source:refseq;acc:nm\_006442]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2416\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
8048.38\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7752.09\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.03822\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 1 (ec 2.7.1.-) (map kinase kinase 1) (mapkk 1) (erk activator kinase 1) (mapk/erk kinase 1) (mek1). [source:swissprot;acc:q02750]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1428\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5880.37\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
6334.71\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.07726\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 2 (ec 2.7.1.-) (map kinase kinase 2) (mapkk 2) (erk activator kinase 2) (mapk/erk kinase 2) (mek2). [source:swissprot;acc:p36507]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1430\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 3 (ec 2.7.1.-) (map kinase kinase 3) (mapkk 3) (mapk/erk kinase 3). [source:swissprot;acc:p46734]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1352\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6104.11\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6586.48\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07902\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 4 (ec 2.7.1.-) (map kinase kinase 4) (jnk activating kinase 1) (c-jun n- terminal kinase kinase 1) (jnkk) (sapk/erk kinase 1) (sek1). [source:swissprot;acc:p45985]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1813\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5866.19\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6245.4\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06464\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 6 (ec 2.7.1.-) (map kinase kinase 6) (mapkk 6) (mapk/erk kinase 6) (sapkk3). [source:swissprot;acc:p52564]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1351\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6105.23\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6587.88\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07906\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 7 (ec 2.7.1.-) (map kinase kinase 7) (mapkk 7) (mapk/erk kinase 7) (jnk activating kinase 2) (c-jun n-terminal kinase kinase 2) (jnk kinase 2) (jnkk 2). [source:swissprot;acc:o14733]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1832\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5633.44\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5997\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06454\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual specificity protein phosphatase 11 (ec 3.1.3.48) (rna/rnp complex-intereracting phosphatase) (phosphatase that interacts with rna/rnp complex 1). [source:swissprot;acc:o75319]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2926\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dual-specificity tyrosine-phosphorylation regulated kinase 1a (ec 2.7.1.-) (protein kinase minibrain homolog) (mnbh) (hp86) (dual specificity yak1-related kinase). [source:swissprot;acc:q13627]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1343\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5887.86\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
6354.5\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07925\vspace{3pt}}\\\cline{1-2}\cline{4-5}
\parbox{\wcA}{\vspace{3pt}\noindent
dual-specificity tyrosine-phosphorylation regulated kinase 1b (ec 2.7.1.-) (mirk protein kinase). [source:swissprot;acc:q9y463]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1342\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
6354.51\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07926\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dymeclin. [source:refseq;acc:nm\_017653]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2140\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5859.1\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6173.7\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05369\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynactin 4. [source:refseq;acc:nm\_032486]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2412\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4644.04\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4470.47\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.03883\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynactin complex 50 kda subunit (50 kda dynein-associated polypeptide) (dynamitin) (dctn-50) (dynactin 2). [source:swissprot;acc:q13561]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1116\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5322.16\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5798.38\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08948\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynamin 1-like protein isoform 3; dynamin-like protein. [source:refseq;acc:nm\_005690]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1702\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6326.24\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6762.27\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06892\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynein 2 light intermediate chain. [source:refseq;acc:nm\_016008]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2962\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
dynein intermediate chain 1, axonemal (axonemal dynein intermediate chain 1). [source:swissprot;acc:q9ui46]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3029\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynein intermediate chain 1, cytosolic (dh ic-1) (cytoplasmic dynein intermediate chain 1). [source:swissprot;acc:o14576]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
617\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5162.52\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5822.47\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.12783\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynein intermediate chain 2, cytosolic (dh ic-2) (cytoplasmic dynein intermediate chain 2). [source:swissprot;acc:q13409]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
611\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5148.71\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5811.74\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.12878\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dynein light chain 2. [source:refseq;acc:nm\_080677]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2701\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5239.33\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5260\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00395\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dyskerin (nucleolar protein nap57) (cbf5 homolog). [source:swissprot;acc:o60832]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2666\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4591.08\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4621.88\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00671\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dystrobrevin alpha (dystrobrevin-alpha). [source:swissprot;acc:q9y4j8]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1763\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5829.73\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6218.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06668\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dystrobrevin beta (beta-dystrobrevin) (dtn-b). [source:swissprot;acc:o60941]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1773\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5829.51\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6218.11\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06666\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dystrobrevin binding protein 1; dysbindin. [source:refseq;acc:nm\_032122]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1230\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5678.02\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6161.65\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08518\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
dystrophin. [source:swissprot;acc:p11532]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1769\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5829.61\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6218.27\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06667\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
e-1 enzyme. [source:refseq;acc:nm\_021204]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
893\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6603.09\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7274.72\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.10171\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
e1a binding protein p400; p400 swi2/snf2-related protein; cagh32 protein; trinucleotide repeat containing 12. [source:refseq;acc:nm\_015409]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1456\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5672.25\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6104.01\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07612\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
e1b-55kda-associated protein 5 isoform a. [source:refseq;acc:nm\_007040]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2693\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4113.79\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4095.53\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00446\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
e2a-pbx1-associated protein; putative 47 kda protein. [source:refseq;acc:nm\_020140]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
494\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5979.93\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6842.72\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.14428\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eap30 subunit of ell complex. [source:refseq;acc:nm\_007241]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
497\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4682.87\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4093.05\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.1441\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
early endosome antigen 1, 162kd; early endosome-associated protein. [source:refseq;acc:nm\_003566]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2151\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4871.11\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5129.63\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05307\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ebp50-pdz interactor of 64 kda (epi64 protein). [source:swissprot;acc:q9bxi6]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
651\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5168.43\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4597.44\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.1242\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ecotropic viral integration site 5; neuroblastoma stage 4s gene. [source:refseq;acc:nm\_005665]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1235\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5807.83\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6300.47\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08482\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ecotropic virus integration 1 site protein. [source:swissprot;acc:q03112]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3170\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
egf-like-domain, multiple 7; neu1 protein. [source:refseq;acc:nm\_016215]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1481\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3688.8\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3431.33\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07504\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eh-domain containing protein 1 (testilin) (hpast1). [source:swissprot;acc:q9h4m9]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2514\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6203.92\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6360.25\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0252\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eh-domain containing protein 2. [source:swissprot;acc:q9nzn4]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2517\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6203.96\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6360.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02519\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eh-domain containing protein 3. [source:swissprot;acc:q9nzn3]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2515\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6203.94\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6360.25\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0252\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eh-domain containing protein 4 (eh domain-containing protein fksg7) (hepatocellular carcinoma-associated protein 10/11). [source:swissprot;acc:q9h223]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2516\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6203.95\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6360.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02519\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
eif-5a2 protein. [source:refseq;acc:nm\_020390]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1610\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6222.4\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6665.83\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07126\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elac homolog 2; putative prostate cancer susceptibility protein; elac (e. coli) homolog 2. [source:refseq;acc:nm\_018127]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2206\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5076.73\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5326.29\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.04916\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elav-like protein 1 (hu-antigen r) (hur). [source:swissprot;acc:q15717]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2178\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5893.23\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6193.33\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05092\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elav-like protein 2 (hu-antigen b) (hub) (elav-like neuronal protein 1) (nervous system-specific rna binding protein hel-n1). [source:swissprot;acc:q12926]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2180\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5900.25\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6200.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05084\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elav-like protein 3 (hu-antigen c) (huc) (paraneoplastic cerebellar degeneration-associated antigen) (paraneoplastic limbic encephalitis antigen 21). [source:swissprot;acc:q14576]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2177\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5887.43\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6187.82\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05102\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elav-like protein 4 (paraneoplastic encephalomyelitis antigen hud) (hu-antigen d). [source:swissprot;acc:p26378]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2179\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5896.51\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6196.59\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05089\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
electron transfer flavoprotein alpha-subunit, mitochondrial precursor (alpha-etf). [source:swissprot;acc:p13804]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1749\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7919.76\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8452.01\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06721\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
electron transfer flavoprotein beta-subunit (beta-etf). [source:swissprot;acc:p38117]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1761\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7794.41\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8316.04\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06692\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial precursor (ec 1.5.5.1) (etf-qo) (etf-ubiquinone oxidoreductase) (etf dehydrogenase) (electron-transferring- flavoprotein dehydrogenase). [source:swissprot;acc:q16134]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1301\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6618.74\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7161.67\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08203\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elks protein. [source:refseq;acc:nm\_015064]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1163\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5832.13\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6343.59\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0877\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ell-associated factor 2; uncharacterized bone marrow protein bm040; testosterone regulated apoptosis inducer and tumor suppressor. [source:refseq;acc:nm\_018456]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2921\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
elongation factor 1-alpha 1 (ef-1-alpha-1) (elongation factor 1 a-1) (eef1a-1) (elongation factor tu) (ef-tu). [source:swissprot;acc:p04720]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1733\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5874.83\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6272.26\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06765\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/